TY - JOUR
T1 - Hepatitis B Virus Infection
T2 - Current Trends and Issues
AU - Furusyo, Norihiro
AU - shimizu, motohiro
AU - Ogawa, Eijchi
AU - Murata, Masayuki
AU - Hayashi, Jun
PY - 2015/6/1
Y1 - 2015/6/1
N2 - Hepatitis B virus (HBV) infection is a global public health problem. HBV has been classified into eight genotypes (A to H) based on complete nucleotide sequencing. The prevalence of specific genotype varies geographically. The rationale for treatment in patients with chronic hepatitis B is to reduce the risk of progressive chronic liver disease, such as cirrhosis and hepatocellular carcinoma. Treatment strategies for chronic HBV infection include interferon and nucleotide analogues (lamivudine, adefovir dipivoxil, entecavir, and tenofovir disoproxil). HBV persists in the body even after serological recovery from acute hepatitis B. Thus, individuals who have been exposed to HBV are at risk of the reactivation of infection, which may result in an increase in serum aminotransferases or a flare when the immune response is suppressed. Patients requiring immunosuppressive therapy should undergo serologic testing for markers of HBV infection. This topic review summarizes these issues related to the management of hepatitis B.
AB - Hepatitis B virus (HBV) infection is a global public health problem. HBV has been classified into eight genotypes (A to H) based on complete nucleotide sequencing. The prevalence of specific genotype varies geographically. The rationale for treatment in patients with chronic hepatitis B is to reduce the risk of progressive chronic liver disease, such as cirrhosis and hepatocellular carcinoma. Treatment strategies for chronic HBV infection include interferon and nucleotide analogues (lamivudine, adefovir dipivoxil, entecavir, and tenofovir disoproxil). HBV persists in the body even after serological recovery from acute hepatitis B. Thus, individuals who have been exposed to HBV are at risk of the reactivation of infection, which may result in an increase in serum aminotransferases or a flare when the immune response is suppressed. Patients requiring immunosuppressive therapy should undergo serologic testing for markers of HBV infection. This topic review summarizes these issues related to the management of hepatitis B.
UR - http://www.scopus.com/inward/record.url?scp=84955759815&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84955759815&partnerID=8YFLogxK
M3 - Review article
C2 - 26548241
AN - SCOPUS:84955759815
SN - 0047-1860
VL - 63
SP - 755
EP - 761
JO - Rinsho byori. The Japanese journal of clinical pathology
JF - Rinsho byori. The Japanese journal of clinical pathology
IS - 6
ER -
